Nuformix PLC is a pharmaceutical development company. It is focused on building value for shareholders through its activities in drug development and by out-licensing. The company uses cocrystal technology to re-engineer the crystalline form of known small molecule drugs. Its pipeline products include NXP001, NXP002, and NXP004. Geographically, the company operates only in the UK.